logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

CHANJET (01588) spent 197,100 Hong Kong dollars on December 9 to repurchase 24,400 shares.

date
19:08 09/12/2025
avatar
GMT Eight
Changjiu Communications (01588) announced that on December 9, 2025, the company spent 197,100 Hong Kong dollars to repurchase 24,400 shares, with a repurchase price of 7.91-8.29 Hong Kong dollars per share.
CHANJET (01588) announced on December 9, 2025 that the company will spend HK$197,100 to repurchase 24,400 shares, with a repurchase price of HK$7.91-8.29 per share.
Related Articles
China Stock
Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject enrolled in the clinical trial of SQ-22031 eye drops for the treatment of moderate to severe dry eye syndrome stage II.
HK Stock
Xuanwu Cloud (02392) spent HK$2263.27 on December 9 to repurchase 2000 shares.
China Stock
Shareholder Zhang Yunlan of Qingdao Kutesmart Co., Ltd. (300840.SZ) plans to reduce their shareholding by not more than 2%.
Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject enrolled in the clinical trial of SQ-22031 eye drops for the treatment of moderate to severe dry eye syndrome stage II.
China Stock
Xuanwu Cloud (02392) spent HK$2263.27 on December 9 to repurchase 2000 shares.
HK Stock
Shareholder Zhang Yunlan of Qingdao Kutesmart Co., Ltd. (300840.SZ) plans to reduce their shareholding by not more than 2%.
China Stock
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
icon
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
icon
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
icon
08/12/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.